Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (NCT07468071)
KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
- Novartis Investigative Site — Leuven,
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Sherbrooke, Quebec
- Novartis Investigative Site — Guangzhou, Guangdong
- Novartis Investigative Site — Copenhagen,
- Novartis Investigative Site — Bron,
- Novartis Investigative Site — Milan, MI
- Novartis Investigative Site — Milan, MI
- Novartis Investigative Site — Roma, RM
- Novartis Investigative Site — Kashiwa, Chiba
- Novartis Investigative Site — Koto Ku, Tokyo
- Novartis Investigative Site — Kuching, Sarawak
- Novartis Investigative Site — Seoul,
- Novartis Investigative Site — Pamplona, Navarre
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.